Belfer
Neurodegeneration
Consortium
Breakthrough Therapies for
Brain Diseases
Mission
Our mission is to discover therapies that slow, stop, or reverse neurodegenerative diseases.
Who We Are
The Belfer Neurodegeneration Consortium (BNDC) is a multi-institutional research consortium mobilizing innovative investigators against neurodegenerative diseases.
The BNDC unites the drug discovery capabilities of MD Anderson Cancer Center Therapeutics Discovery Division with leading neuroscientists at MIT, Mount Sinai School of Medicine, Baylor College of Medicine, NYU Grossman School of Medicine and UT Health Science Center San Antonio. Launched in 2012, the BNDC is funded by the Robert A. and Reneé E. Belfer family foundation, Oskar Fischer Project, and many other philanthropic donors and funding agencies.
The BNDC is part of the Therapeutics Discovery Division at MD Anderson Cancer Center. This is a team of over 150 dedicated researchers, clinicians, drug developers and scientific experts that develop transformative therapies ranging from small molecule, biologics to cell therapies.
"The BNDC has the opportunity to change the lives of patients suffering from neurological disorders. This is the great challenge of our time."
~Jim Ray, Ph.D.
